Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Short Interest Update

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 25,588 shares, a decline of 23.5% from the November 30th total of 33,462 shares. Based on an average daily volume of 3,281,479 shares, the short-interest ratio is presently 0.0 days. Approximately 0.2% of the shares of the company are sold short. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 3,281,479 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on RADX. B. Riley reaffirmed a “buy” rating and set a $16.00 price target (up from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Radiopharm Theranostics presently has a consensus rating of “Buy” and an average price target of $15.33.

Radiopharm Theranostics Trading Down 3.9%

NASDAQ RADX traded down $0.21 during trading on Tuesday, hitting $5.16. The stock had a trading volume of 67,994 shares, compared to its average volume of 247,236. Radiopharm Theranostics has a 12 month low of $3.50 and a 12 month high of $16.25. The company’s 50-day moving average price is $5.01 and its two-hundred day moving average price is $5.27.

Institutional Investors Weigh In On Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. bought a new position in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned about 0.10% of Radiopharm Theranostics at the end of the most recent reporting period.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.